Channing Capital Management, LLC Gilead Sciences, Inc. Transaction History

Channing Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $7.81 Million - $10 Million	-124,753 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $35,554 - $39,109	-577 Reduced 0.46%	124,753 $8.11 Million
Q3 2019 Nov 12, 2019	BUY	$62.51 - $69.0 $776,124 - $856,704	12,416 Added 11.0%	125,330 $7.94 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $1.31 Million - $1.47 Million	21,225 Added 23.15%	112,914 $7.63 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $5.73 Million - $6.42 Million	91,689 New	91,689 $5.96 Million
Q2 2018 Jul 20, 2018	SELL	$64.88 - $75.68 $7.17 Million - $8.37 Million	-110,567 Closed	0 $0
Q1 2018 Apr 24, 2018	BUY	$72.84 - $88.8 $10,853 - $13,231	149 Added 0.13%	110,567 $8.34 Million
Q4 2017 Feb 13, 2018	BUY	$71.15 - $83.52 $213 - $250	3 Added 0.0%	110,418 $7.91 Million
Q3 2017 Oct 31, 2017	BUY	$72.11 - $85.47 $7.96 Million - $9.44 Million	110,415	110,415 $8.95 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Channing Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Channing Capital Management, LLC with notifications on news.